## **Minimum Laboratory Monitoring For Psychotropic Medications**



ANTIPSYCHOTIC MEDICATIONS				
GENERIC	BRAND	GENERIC	BRAND	
Aripiprazole	Abilify, Abilify Maintena, Aristada	Olanzapine	Zyprexa, Zyprexa Zydis	
Asenapine	Saphris	Paliperidone	Invega, Invega Sustenna, Invega Trinza	
Brexpiprazole	Rexulti	Perphenazine	Trilafon	
Cariprazine	Vraylar	Pimozide	Orap	
Chlorpromazine	Thorazine	Quetiapine	Seroquel, Seroquel XR	
Clozapine	Clozaril, Fazaclo	Risperidone	Risperdal, Risperdal Consta, Risperdal M Tabs	
Fluphenazine, Fluphenazine D	Prolixin, Prolixin D	Thioridazine	Mellaril	
Haloperidol, Haloperidol D	Haldol, Haldol D	Thiothixene	Navane	
lloperidone	Fanapt	Trifluoperazine	Stelazine	
Loxapine	Loxitane	Ziprasidone	Geodon	
Lurasidone	Latuda			

MONITORING	ANTIPSYCHOTIC FREQUENCY OF MONITORING
AIMS (Abnormal Involuntary Movement Scale)	On initiation of any antipsychotic medication and at least every six months thereafter, or more frequently as clinically indicated.
ABDOMINAL GIRTH (≥18 years old)	For individuals at least 18 years old, on initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated.
WEIGHT & BODY MASS INDEX (BMI)	On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated.
HEART RATE & BLOOD PRESSSURE	On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated.
COMPREHENSIVE METABOLIC PANEL (CMP), LIPIDS, FASTING GLUCOSE AND COMPLETE BLOOD COUNT (CBC)	On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as clinically indicated.

CLOZAPINE MONITORING		
MONITORING	FREQUENCY OF MONITORING	
White Blood Cell Count (WBC) w/ Absolute Neutrophil	Weekly for 1st 6 months (if values within normal limits), then every 2 wks. for	
Count (ANC)	6 months, then monthly (if values within normal limits)	
Comprehensive Metabolic Panel (CMP)	At least annually	
Fasting Lipid Panel	At least annually	

LITHIUM MONITORING		
MONITORING	FREQUENCY OF MONITORING	
Lithium Level	Within one month of initiation of lithium or significant change in dose and at least every six months thereafter or more frequently as clinically indicated.	
Thyroid Function	Within one month of initiation of lithium and at least annually thereafter or more frequently as clinically indicated.	
CBC w/ Platelet Count	On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as clinically indicated.	
CMP	Renal function – within one month of initiation of lithium and at least annually thereafter or more frequently as clinically indicated.	

VALPROIC ACID MONITORING		
MONITORING	FREQUENCY OF MONITORING	
Valproic Acid Level and CMP	Within one month of initiation of valproic acid or divalproex or significant change in dose and at least annually thereafter or more frequently as clinically indicated.	
CBC with Platelet Count	On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as clinically indicated.	

CARBAMAZEPINE MONITORING		
MONITORING	FREQUENCY OF MONITORING	
Carbamazepine Level,	Within 1 month of initiation of carbamazepine or significant change in dose and at least annually thereafter or	
CMP and TSH	more frequently as clinically indicated.	
CBC w/ Platelet Count	On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as	
	clinically indicated.	

Updated: 7/2019